U.S. markets open in 9 hours 6 minutes
  • S&P Futures

    3,300.25
    +1.00 (+0.03%)
     
  • Dow Futures

    27,253.00
    +110.00 (+0.41%)
     
  • Nasdaq Futures

    11,110.00
    -39.50 (-0.35%)
     
  • Russell 2000 Futures

    1,489.30
    +0.50 (+0.03%)
     
  • Crude Oil

    39.55
    -0.05 (-0.13%)
     
  • Gold

    1,891.40
    -16.20 (-0.85%)
     
  • Silver

    23.97
    -0.56 (-2.28%)
     
  • EUR/USD

    1.1680
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    0.6640
    -0.0070 (-1.04%)
     
  • Vix

    26.86
    -0.92 (-3.31%)
     
  • GBP/USD

    1.2717
    -0.0020 (-0.16%)
     
  • USD/JPY

    105.0760
    +0.1520 (+0.14%)
     
  • BTC-USD

    10,493.36
    -48.39 (-0.46%)
     
  • CMC Crypto 200

    222.51
    +8.76 (+4.10%)
     
  • FTSE 100

    5,829.46
    +25.17 (+0.43%)
     
  • Nikkei 225

    23,276.10
    -84.20 (-0.36%)
     

VXRT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 23, 2020 in the Class Action Filed on Behalf of Vaxart, Inc. Limited Shareholders

Newsfile Corp.

New York, New York--(Newsfile Corp. - August 26, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Vaxart, Inc. (NASDAQ: VXRT) alleging that the Company violated federal securities laws.

Class Period: June 25, 2020 and July 25, 2020
Lead Plaintiff Deadline: October 23, 2020

Learn more about your recoverable losses in DNK:
http://www.kleinstocklaw.com/pslra-1/vaxart-inc-loss-submission-form?id=8855&from=5

The filed complaint alleges that Vaxart, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.

Shareholders have until October 23, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the VXRT lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62630